AlphAIalphai — Financial news for AI agents
SEC EDGARJUN 32 min read$PGNY

Scott Cheryl sold $196K of PGNY

Scott Cheryl sold 7,439 shares of Progyny, Inc. (PGNY) at $26.38 ($0.20M total) on 2026-06-01.

Original reporting
SEC EDGAR · Scott Cheryl
Published Jun 3, 2026, 8:53 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 3, 2026, 9:01 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$PGNY
Neutral
medium confidence
Mentioned
$PGNY
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PGNYNeutralLow
01

Why it matters

Traders may monitor for follow-on insider activity or correlate with any concurrent company news, but the filing itself is not a fundamental update.

02

Market read

Provides a dated insider sale datapoint that can marginally influence short-term sentiment around PGNY.

03

What to watch

No 10b5-1 plan is cited; however, Form 4s can still reflect pre-planned or non-informational motives, and the article lacks context on total insider holdings or prior sale frequency.

Relevance 6/10Novelty 6/10Timing: SEC Form 4 filed 2026-06-03 (sale dated 2026-06-01)

Background

This is an SEC Form 4 insider transaction disclosure for a Progyny director, reporting an open-market sale of shares.

Company-level read

Ticker impact

$PGNYNeutralMedium confidence
Context

Progyny director Scott Cheryl sold 7,439 shares in an open-market transaction disclosed via SEC Form 4 on 2026-06-01.

Expected impact

Low likelihood of a sustained price move; any effect is likely limited to short-term sentiment/flow.

Evidence & confidence

The filing provides a realized sale price and size, but insider transactions alone rarely change near-term fundamentals without accompanying company-specific news.

Market effects

Sector

Minimal; this is company-specific insider activity with no stated sector-wide development.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

The sale may be routine liquidity/tax-related and does not necessarily reflect a bearish view on Progyny’s prospects.

Key entities

  • issuer
    Progyny, Inc.

    Subject of the SEC Form 4 insider sale disclosure.

  • insider
    Scott Cheryl

    Director who sold 7,439 shares; holdings after transaction were 19,772 shares.

Read at source← All news

Related articles

AUG 7
$PGNYMedAI 8/10

Why Progyny (PGNY) Shares Are Sliding Today

Progyny (PGNY) shares fell about 4.5% after the fertility benefits company issued weaker guidance. Q2 revenue rose to $350.5M (+5.3% YoY) and adjusted EPS was $0.55, both above estimates. But it projected $340M revenue for the next quarter, about 3% below consensus, and cut full-year revenue to $1.37B from $1.39B.

financialcontent.com5 min
AUG 7
$PGNYMed

Why Progyny Stock Plunged, Then Gradually Recovered Today

Progyny (PGNY) shares fell about 6% after its Q2 earnings. The company reported 5% sales growth, with adjusted EPS up 15% versus expectations. Q3 sales guidance calls for 7% to 11% growth and adjusted earnings are slightly lower sequentially. Gross margins rose 180 bps and covered members increased 7% to 7.2 million.

yahoo.com3 min
AUG 6
$PGNYMed

Progyny, Inc. (PGNY): Results of Operations and Financial Condition

Progyny, Inc. (PGNY) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exhibit991q22026.htm EX-99.1 Document Progyny, Inc. Announces Second Quarter 2026 Results Reports Record Quarterly Revenue, Gross Profit and Adjusted EBITDA Robust Selling Season Activity Continues to Reflect Strong Demand for Women's Health, Family Building Solutions V

SEC EDGAR 8-K4 min
JUL 13
$PGNYMed

Progyny (PGNY) Stock Is Up, What You Need To Know

Progyny (PGNY) shares rose 3.5% to $31.73 after KeyBanc raised its price target to $35 from $30 and kept an Overweight rating, citing expectations for a strong earnings report and higher future guidance. The article also notes other bullish analyst actions, including Truist raising its target and Canaccord upgrading to Buy.

financialcontent.com4 min
MAY 31
$PGNYMedAI 8/10

A Progyny (PGNY) Insider Sold 5,500 Shares for $137,000

Progeny (PGNY) director Kevin Gordon sold 5,500 shares for about $137,000, according to the article. The firm reported Q1 revenue of $328 million, up 1.4% YoY, with gross profit rising 10% to $83.1 million. It said client growth and retention were strong aside from a large client loss, and approved a $200 million share repurchase program.

finance.yahoo.com5 min